| Date Filed | Type | Description |
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/11/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/25/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/23/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/15/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/09/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events Interactive Data |
| 03/01/2023 |
IRANNOTICE
| Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).: |
| 03/01/2023 |
10-Q
| Quarterly Report for the period ended January 27, 2023 |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.4% stake in Medtronic plc |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/12/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/01/2022 |
IRANNOTICE
| Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).: |
| 12/01/2022 |
10-Q
| Quarterly Report for the period ended October 28, 2022 |
| 11/22/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
| 10/25/2022 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
| 09/21/2022 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 09/21/2022 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 09/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Medtronic Global Holdings S.C.A., Medtronic plc and Medtronic, Inc., and Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe, as representatives of the several underwriters named therein",
"Fifth Supplemental Indenture, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes)",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, U.S. counsel to Medtronic plc, Medtronic Global Holdings S.C.A. and Medtronic, Inc",
"Opinion of A&L Goodbody, Irish counsel to Medtronic plc",
"Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A",
"Opinion of Thomas L. Osteraas, Legal Director - Corporate and Securities of Medtronic, Inc" |
|
| 09/16/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/15/2022 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/15/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 09/01/2022 |
10-Q
| Quarterly Report for the period ended July 29, 2022 |
| 08/23/2022 |
8-K
| Quarterly results |
|